Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

LPCN Lipocine Inc.
$2.19 2.82% +0.06
Notify me if price changes either direction
Interactive Brokers Logotype

Buy LPCN stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 17.6M
Enterprise value -7251254
Trailing PE -1.2372881355932
Forward PE -1.7016128
PEG Ratio -0.022792149866191
Enterprise to EBITDA 0.601
Enterprise to revenue -3.622
Price to book MRQ 0.69089717
Price to sales TTM 8.688086

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-03-31
Revenue (TTM) 2.0M
EBITDA -12070633
Diluted EPS TTM -1.96
Total Cash (MRQ) 24.7M
Current ratio (MRQ) 9.987
Operating Cash Flow (TTM) -10048601

LPCN trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent LPCN News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.